Mr. Kiritsy is a seasoned entrepreneur with more than two decades of business and technical experience from senior positions in corporate management, finance, research and development, and business development. At Arisaph, Mr. Kiritsy has evolved the organization from an academic, research orientation to a clinical development enterprise with a rich research pipeline, which led to one of the highest awards from the U.S. government’s Therapeutics Discovery Project Program totaling nearly $3 million with all 12 projects funded. Additionally, Mr. Kiritsy has executed multiple business development transactions, leveraging Arisaph’s strong intellectual property to raise nearly $60 million of non-dilutive capital. Prior to Arisaph, Mr. Kiritsy served as executive vice president, corporate development and chief financial officer of Kos Pharmaceuticals, Inc., where he played a key operating role in building the company from a start-up organization to a highly profitable, 1,200-person publicly traded enterprise. During his tenure at Kos, Mr. Kiritsy raised approximately $500 million in public equity capital, including Kos’ IPO, and spearheaded more than 10 major corporate development transactions. In 2005, Fortune Magazine ranked Kos the fastest growing pharmaceutical company in the U.S. In 2006, Kos was acquired by Abbott Laboratories for $4 billion.
Prior to Kos, Mr. Kiritsy served as associate director of product development at the Institute of Molecular Biology, a private biotechnology company, where he co-authored several publications in various scientific journals. In addition to being member of the board of directors of Melinta Therapeutics, Mr. Kiritsy currently serves as chairman of the board of directors of Avaxia Biologics.
Mr. Kiritsy received his MBA from Boston University and B.A. in biology from Bowdoin College.